Federated Hermes Inc. Has $133,000 Position in The Joint Corp. (NASDAQ:JYNT)

Federated Hermes Inc. lessened its stake in The Joint Corp. (NASDAQ:JYNT) by 58.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,807 shares of the company’s stock after selling 19,405 shares during the quarter. Federated Hermes Inc. owned 0.09% of Joint worth $133,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JYNT. Quantbot Technologies LP lifted its holdings in shares of Joint by 345.0% during the 3rd quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after buying an additional 3,233 shares during the last quarter. Barclays PLC grew its position in Joint by 29.4% in the third quarter. Barclays PLC now owns 13,725 shares of the company’s stock worth $123,000 after acquiring an additional 3,119 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Joint by 43.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock worth $148,000 after purchasing an additional 4,987 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Joint during the 3rd quarter valued at $179,000. Finally, Strs Ohio lifted its stake in shares of Joint by 69.1% in the 3rd quarter. Strs Ohio now owns 25,200 shares of the company’s stock valued at $226,000 after purchasing an additional 10,300 shares during the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.

Joint Stock Down 2.0 %

Shares of JYNT opened at $15.79 on Tuesday. The company has a 50-day moving average price of $12.17 and a two-hundred day moving average price of $10.21. The stock has a market cap of $235.90 million, a price-to-earnings ratio of -21.05 and a beta of 1.58. The Joint Corp. has a 12 month low of $7.31 and a 12 month high of $16.35.

Joint (NASDAQ:JYNT) last posted its earnings results on Thursday, March 7th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The business had revenue of $30.61 million during the quarter, compared to the consensus estimate of $29.63 million. Joint had a positive return on equity of 3.94% and a negative net margin of 9.24%. Equities research analysts expect that The Joint Corp. will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on JYNT. Roth Mkm restated a “buy” rating and set a $16.00 target price (up from $13.00) on shares of Joint in a report on Friday. B. Riley upped their target price on Joint from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday. StockNews.com upgraded shares of Joint from a “hold” rating to a “buy” rating in a research note on Monday. Finally, TheStreet cut shares of Joint from a “c-” rating to a “d” rating in a report on Thursday, March 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Joint Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.